Joe Rogan on health: what the evidence says · JRE #2051
SUBJECT: HEALTH
The short answer
Rogan reads and endorses a viral claim that fenbendazole (a dog dewormer) has proven, effective anti-cancer mechanisms in humans and is being suppressed from clinical trials because it's too cheap for pharmaceutical companies to profit from. The viral claim traces largely to Joe Tippens, an Oklahoma man with small-cell lung cancer who took fenbendazole alongside vitamin E, CBD oil and curcumin while simultaneously enrolled in a clinical trial of the approved immunotherapy drug pembrolizumab (Keytruda); he was the only patient in that roughly 1,100-person trial to achieve remission, making it impossible to attribute his outcome to fenbendazole specifically.
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
So why are there no fenbendazole clinical trials for cancer? The answer seems rather obvious. It's very cheap, it's safe, and it seems to be effective, very effective.
What the evidence says 01 / RECORD
The viral claim traces largely to Joe Tippens, an Oklahoma man with small-cell lung cancer who took fenbendazole alongside vitamin E, CBD oil and curcumin while simultaneously enrolled in a clinical trial of the approved immunotherapy drug pembrolizumab (Keytruda); he was the only patient in that roughly 1,100-person trial to achieve remission, making it impossible to attribute his outcome to fenbendazole specifically. Fenbendazole has shown anticancer activity against various cancer cell lines in vitro and in some animal (in vivo) models, but no completed human clinical trials have tested it as a cancer treatment, so there is no clinical evidence of efficacy or an established safe cancer-treating dose in humans. Medical and regulatory bodies in multiple countries, including South Korea's Ministry of Food and Drug Safety and its national medical, pharmaceutical, and veterinary associations, have specifically warned patients against using fenbendazole for cancer given the absence of human trial data. The premise that trials are being blocked purely because the drug is too cheap to profit from is an unsubstantiated claim; the barrier described in the scientific literature is the lack of clinical-stage evidence and the funding/regulatory pathways typical for any unpatented drug-repurposing effort, not a documented act of suppression. Preclinical interest in fenbendazole as a repurposed cancer drug is real and ongoing, but as of this claim it remained an unproven, non-standard therapy rather than a demonstrated effective treatment.